Insight

Andrew W Hahn: How effective and tolerable is Belzutifan in treating Sporadic Metastatic Clear Cell Renal Cell Carcinoma

Andy Hahn/X

Oct 7, 2024, 07:05

Andrew W Hahn: How effective and tolerable is Belzutifan in treating Sporadic Metastatic Clear Cell Renal Cell Carcinoma

Andrew W Hahn, Genitourinary Medical Oncologist, MD Anderson Cancer Center, shared a post on X:

“ Check out our single-center, real-world experience with belzutifan in 22 patients with metastatic Clear Cell Renal Cell Carcinoma who were treated prior to the FDA approval. Led by our outstanding pharmacist, Emily Wang.

Belzutifan had meaningful activity in this heavily pre-treated cohort with ORR of 36.4%, median PFS of 8.5 months, and median OS of 14.7 months. We provide a detailed summary of the responders to belzutifan and our experience managing AEs of hypoxia and anemia.“

Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma

Authors: Emily Wang, Eric S Rupe, Sagar S Mukhida, Andrew C Johns, Matthew T Campbell, Amishi Y Shah, Amado J Zurita, Jianjun Gao, Sangeeta Goswami, Eric Jonasch, Pavlos Msaouel, Nizar M Tannir and Andrew W Hahn.

Source: Andy Hahn/X

Amado J Zurita Amishi Y Shah Andrew C Johns Andrew W Hahn Andy Hahn belzutifan cancer cancer awareness cancer care Emily Wang Eric Jonasch Eric S Rupe fight against cancer Global fight against cancer Jianjun Gao Matthew T Campbell Nizar M. Tannir OncoDaily Oncology Pavlos Msaouel RENAL CARCINOMA Sagar S Mukhida Sangeeta Goswami

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage